AdaptHealth Diabetes Health Divestiture to Cardinal Health | Lucid Diligence Brief
AdaptHealth exits its Diabetes Health business in a $235 million deal as…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
DermaSensor AI dermatology devices | Lucid Diligence Brief
AI dermatology devices are advancing beyond validation studies as DermaSensor…
GNI Group Acquires Ayumi Pharmaceutical | Lucid Diligence Brief
GNI Group’s Ayumi acquisition tests Japan commercial scale, Calonal durability,…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: Glooko and mylife Diabetes Care expand diabetes data partnership
Lucid Diligence Brief: Glooko and mylife Diabetes Care expand diabetes data…
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on AI-powered subdural hemorrhage care
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on…
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…